董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Warren Huff | 男 | Chief Executive Officer, President and Chairman of the Board of Director | 72 | 455.48万美元 | 未持股 | 2020-02-19 |
| James E. Bass | 男 | Director | 67 | 10.89万美元 | 未持股 | 2020-02-19 |
| R. Kent McGaughy, Jr. | 男 | Director | 55 | 14.00万美元 | 未持股 | 2020-02-19 |
| William E. Rose | 男 | Director | 58 | 12.53万美元 | 未持股 | 2020-02-19 |
| William D. McClellan, Jr. | 男 | Director | 66 | 未披露 | 未持股 | 2020-02-19 |
| Jack B. Nielsen | 男 | Director | 62 | 未披露 | 未持股 | 2020-02-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Warren Huff | 男 | Chief Executive Officer, President and Chairman of the Board of Director | 72 | 455.48万美元 | 未持股 | 2020-02-19 |
| Colin Meyer | 男 | Chief Medical Officer and Executive Vice President, Product Development | 47 | 268.89万美元 | 未持股 | 2020-02-19 |
| Jason D. Wilson | 男 | Executive Vice President, Operations | 57 | 未披露 | 未持股 | 2020-02-19 |
| Michael D. Wortley | 男 | Chief Legal Officer and Executive Vice President | 79 | 未披露 | 未持股 | 2020-02-19 |
| Manmeet S. Soni | 男 | Chief Financial Officer and Executive Vice President | 48 | 未披露 | 未持股 | 2020-02-19 |
| Dawn C. Bir | 女 | Chief Commercial Officer and Executive Vice President | 55 | 未披露 | 未持股 | 2020-02-19 |
董事简历
中英对照 | 中文 | 英文- J. Warren Huff
-
J. Warren Huff，是Reata Pharmaceuticals的董事长、首席执行官和总裁。他从我们公司2002年创立起担任首席执行官、总裁和董事长。创立Reata前，他曾在许多健康护理和信息技术初创企业（包括Ergo Science Corporation, Light Biology Inc., OpenPages, Inc.和InLight Corporation）担任首席执行官。他起初在Johnson & Gibbs, P.C。担任律师开始他的职业生涯；曾在该公司担任Corporate Securities Practice合伙人和董事长。他持有以优异成绩从德州大学奥斯丁分校获得的工商管理学士学位，以及Southern Methodist大学获得的法学博士学位。
J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole CEO, President and as Chairman of the Board since our founding in 2002. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University. - J. Warren Huff，是Reata Pharmaceuticals的董事长、首席执行官和总裁。他从我们公司2002年创立起担任首席执行官、总裁和董事长。创立Reata前，他曾在许多健康护理和信息技术初创企业（包括Ergo Science Corporation, Light Biology Inc., OpenPages, Inc.和InLight Corporation）担任首席执行官。他起初在Johnson & Gibbs, P.C。担任律师开始他的职业生涯；曾在该公司担任Corporate Securities Practice合伙人和董事长。他持有以优异成绩从德州大学奥斯丁分校获得的工商管理学士学位，以及Southern Methodist大学获得的法学博士学位。
- J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole CEO, President and as Chairman of the Board since our founding in 2002. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.
- James E. Bass
-
James E. Bass，从2004年7月起担任我们董事会成员。他是Snowbird Holdings, LLC 和Trinity Summits, LLC.的管理者董事会成员。过去的5年，他一直管理家族资产和投资，作为他的起初商业活动。他此前担任FB Gemini Limited（香港一家亚洲区域投资银行）的执行董事，此后在Gibson, Dunn & Crutcher LLP担任助理律师和随后担任合伙人。他毕业于耶鲁大学持有学士学位，并持有斯坦福大学的法学博士学位。
James E. Bass has served as a member of the Board since July 2004. For the past five years, Mr. Bass has been managing family assets and investments as his primary business activity. Mr. Bass is a member of the board of Snowbird Holdings, LLC and Trinity Summits, LLC. Mr. Bass graduated with a B.A. from Yale University and obtained his J.D. from Stanford University. - James E. Bass，从2004年7月起担任我们董事会成员。他是Snowbird Holdings, LLC 和Trinity Summits, LLC.的管理者董事会成员。过去的5年，他一直管理家族资产和投资，作为他的起初商业活动。他此前担任FB Gemini Limited（香港一家亚洲区域投资银行）的执行董事，此后在Gibson, Dunn & Crutcher LLP担任助理律师和随后担任合伙人。他毕业于耶鲁大学持有学士学位，并持有斯坦福大学的法学博士学位。
- James E. Bass has served as a member of the Board since July 2004. For the past five years, Mr. Bass has been managing family assets and investments as his primary business activity. Mr. Bass is a member of the board of Snowbird Holdings, LLC and Trinity Summits, LLC. Mr. Bass graduated with a B.A. from Yale University and obtained his J.D. from Stanford University.
- R. Kent McGaughy, Jr.
-
R. Kent McGaughy, Jr.自2004年12月起担任董事会成员。McGaughy先生自2006年以来一直是CPMG，Inc.的合伙人。在加入CPMG的前身Cardinal Investment Company，Inc.之前，他于1997年在Simmons & Company International工作。他目前在上市公司Apollo Endosurgery, Inc.和几家私营公司的董事会任职。McGaughy先生获得了学士学位。以优异成绩获得德克萨斯大学和Phi Beta Kappa成员，并获得哈佛商学院的工商管理硕士学位。
R. Kent McGaughy, Jr. has served as a member of the Board since December 2004. Mr. McGaughy has been a partner in CPMG, Inc. since 2006. Prior to joining CPMG's predecessor, Cardinal Investment Company, Inc., in 1997 he worked at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly traded company, and several private companies. Mr. McGaughy received his B.A. from The University of Texas summa cum laude and member of Phi Beta Kappa and his M.B.A. from Harvard Business School. - R. Kent McGaughy, Jr.自2004年12月起担任董事会成员。McGaughy先生自2006年以来一直是CPMG，Inc.的合伙人。在加入CPMG的前身Cardinal Investment Company，Inc.之前，他于1997年在Simmons & Company International工作。他目前在上市公司Apollo Endosurgery, Inc.和几家私营公司的董事会任职。McGaughy先生获得了学士学位。以优异成绩获得德克萨斯大学和Phi Beta Kappa成员，并获得哈佛商学院的工商管理硕士学位。
- R. Kent McGaughy, Jr. has served as a member of the Board since December 2004. Mr. McGaughy has been a partner in CPMG, Inc. since 2006. Prior to joining CPMG's predecessor, Cardinal Investment Company, Inc., in 1997 he worked at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly traded company, and several private companies. Mr. McGaughy received his B.A. from The University of Texas summa cum laude and member of Phi Beta Kappa and his M.B.A. from Harvard Business School.
- William E. Rose
-
William E. Rose自2016年2月起担任公司董事。Rose是Montrose Capital, Inc.总裁。加入Montrose之前，Rose从1991年到2012年担任HBK Capital Management合伙人，担任过多个职位，包括联合首席投资官。他现任Greenhill School信托董事长；Dallas Museum of Art投资委员会成员。Rose于1989年获得Duke University政治科学文学学位学位。
William E. Rose has served as a member of the Board since February 2016. Mr. Rose is the President of Montrose Capital, Inc. Prior to Montrose, Mr. Rose was associated with HBK Capital Management from 1991 until 2012 serving in various capacities, including Co-Chief Investment Officer. He currently serves on the Board of Greenhill School and is also a member of the Investment Committee for the Dallas Museum of Art. Mr. Rose received a B.A. in Political Science from Duke University in 1989. - William E. Rose自2016年2月起担任公司董事。Rose是Montrose Capital, Inc.总裁。加入Montrose之前，Rose从1991年到2012年担任HBK Capital Management合伙人，担任过多个职位，包括联合首席投资官。他现任Greenhill School信托董事长；Dallas Museum of Art投资委员会成员。Rose于1989年获得Duke University政治科学文学学位学位。
- William E. Rose has served as a member of the Board since February 2016. Mr. Rose is the President of Montrose Capital, Inc. Prior to Montrose, Mr. Rose was associated with HBK Capital Management from 1991 until 2012 serving in various capacities, including Co-Chief Investment Officer. He currently serves on the Board of Greenhill School and is also a member of the Investment Committee for the Dallas Museum of Art. Mr. Rose received a B.A. in Political Science from Duke University in 1989.
- William D. McClellan, Jr.
-
WilliamD.McClellan，Jr.，自2014年5月起担任我们的董事会成员。自2018年1月起，McClellan先生担任Aerin Medical Inc.的首席财务官。自2016年4月以来，McClellan先生一直担任梦百合和生命科学公司的财务管理顾问，并担任Goodwater Consulting，LLC的管理成员。2004年6月至2016年6月，McClellan先生担任医疗设备制造商On-X Life Technologies Holdings，Inc.的首席财务官兼执行Vice President。他目前任职于Reata制药公司公司（一家公开上市的制药公司）的董事会，并担任其审计委员会主席。McClellan先生在阿比林基督教大学（Abilene Christian University）获得会计学B.B.A.，是一名注册会计师。
William D. McClellan, Jr.,Since May 2014has served as a member of our Board. Since January 2018 Mr. McClellan has served as the Chief Financial Officer of Aerin Medical Inc. Since April 2016 Mr. McClellan has served as a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC. From June 2004 until June 2016 Mr. McClellan was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc., a medical device manufacturer. He currently serves on the Board of Directors of Reata Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, and chairs its audit committee. Mr. McClellan received a B.B.A. in accounting from Abilene Christian University and is a Certified Public Accountant. - WilliamD.McClellan，Jr.，自2014年5月起担任我们的董事会成员。自2018年1月起，McClellan先生担任Aerin Medical Inc.的首席财务官。自2016年4月以来，McClellan先生一直担任梦百合和生命科学公司的财务管理顾问，并担任Goodwater Consulting，LLC的管理成员。2004年6月至2016年6月，McClellan先生担任医疗设备制造商On-X Life Technologies Holdings，Inc.的首席财务官兼执行Vice President。他目前任职于Reata制药公司公司（一家公开上市的制药公司）的董事会，并担任其审计委员会主席。McClellan先生在阿比林基督教大学（Abilene Christian University）获得会计学B.B.A.，是一名注册会计师。
- William D. McClellan, Jr.,Since May 2014has served as a member of our Board. Since January 2018 Mr. McClellan has served as the Chief Financial Officer of Aerin Medical Inc. Since April 2016 Mr. McClellan has served as a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC. From June 2004 until June 2016 Mr. McClellan was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc., a medical device manufacturer. He currently serves on the Board of Directors of Reata Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, and chairs its audit committee. Mr. McClellan received a B.B.A. in accounting from Abilene Christian University and is a Certified Public Accountant.
- Jack B. Nielsen
-
Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
Jack B. Nielsen has served as a member our board of directors since August 2018. Since August 2017 Mr. Nielsen has also served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm. Prior to March, 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012 Mr. Nielsen was employed as a Partner at Novo Ventures US Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo Holdings A/S. Mr. Nielsen is currently a member of the board of directors of Reata Pharmaceuticals, Inc. and ALX Oncology Holdings Inc., both of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark. - Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
- Jack B. Nielsen has served as a member our board of directors since August 2018. Since August 2017 Mr. Nielsen has also served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm. Prior to March, 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012 Mr. Nielsen was employed as a Partner at Novo Ventures US Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo Holdings A/S. Mr. Nielsen is currently a member of the board of directors of Reata Pharmaceuticals, Inc. and ALX Oncology Holdings Inc., both of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark.
高管简历
中英对照 | 中文 | 英文- J. Warren Huff
J. Warren Huff，是Reata Pharmaceuticals的董事长、首席执行官和总裁。他从我们公司2002年创立起担任首席执行官、总裁和董事长。创立Reata前，他曾在许多健康护理和信息技术初创企业（包括Ergo Science Corporation, Light Biology Inc., OpenPages, Inc.和InLight Corporation）担任首席执行官。他起初在Johnson & Gibbs, P.C。担任律师开始他的职业生涯；曾在该公司担任Corporate Securities Practice合伙人和董事长。他持有以优异成绩从德州大学奥斯丁分校获得的工商管理学士学位，以及Southern Methodist大学获得的法学博士学位。
J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole CEO, President and as Chairman of the Board since our founding in 2002. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.- J. Warren Huff，是Reata Pharmaceuticals的董事长、首席执行官和总裁。他从我们公司2002年创立起担任首席执行官、总裁和董事长。创立Reata前，他曾在许多健康护理和信息技术初创企业（包括Ergo Science Corporation, Light Biology Inc., OpenPages, Inc.和InLight Corporation）担任首席执行官。他起初在Johnson & Gibbs, P.C。担任律师开始他的职业生涯；曾在该公司担任Corporate Securities Practice合伙人和董事长。他持有以优异成绩从德州大学奥斯丁分校获得的工商管理学士学位，以及Southern Methodist大学获得的法学博士学位。
- J. Warren Huff is the Chairman, Chief Executive Officer and President of Reata. He has served as our sole CEO, President and as Chairman of the Board since our founding in 2002. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.
- Colin Meyer
Colin Meyer，2003年加入Reata成为我们的第一位雇员，是Reata 的首席医疗官。 他持有Virginia大学的化学学士学位，专修化学；以及持有该校的生物学学士学位。他持有Texas大学Southwestern 医学院的医学博士学位，以及Southern Methodist大学Cox 商学院的工商管理硕士学位。
Colin Meyer joined Reata as one of our first employees in 2003 and is Reata’s Chief Medical Officer. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.- Colin Meyer，2003年加入Reata成为我们的第一位雇员，是Reata 的首席医疗官。 他持有Virginia大学的化学学士学位，专修化学；以及持有该校的生物学学士学位。他持有Texas大学Southwestern 医学院的医学博士学位，以及Southern Methodist大学Cox 商学院的工商管理硕士学位。
- Colin Meyer joined Reata as one of our first employees in 2003 and is Reata’s Chief Medical Officer. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.
- Jason D. Wilson
Jason D. Wilson，是Reata的财务总监；监管企业战略、财务、会计和司库、人力资源、业务发展、投资者关系和信息技术。他于2006年加入Reata。此前，他曾在Caris Diagnostics担任财务副总裁和企业财务总监；以及在Ernst & Young LLP。的健康-科学部门担任高级经理。他持有Henderson 大学的会计学士学位和Central Arkansas大学的工商管理硕士学位。
Jason D. Wilson is Reata’s Executive Vice President, Operations and oversees program and clinical operations, manufacturing, human resources, bioinformatics, quality and global alliances. Until August 2019 Mr. Wilson was Reata’s Chief Financial Officer. He joined Reata in 2006. Prior to joining Reata, he held positions as Vice President, Finance & Corporate Controller at Caris Diagnostics and as a Senior Manager in the health-sciences group at Ernst & Young LLP. He served on the board of directors of CytoSen Therapeutics, a private company, until its sale to Kiadis Pharmaceuticals. Mr. Wilson holds a B.B.A. in Accounting from Henderson University and an M.B.A. from University of Central Arkansas.- Jason D. Wilson，是Reata的财务总监；监管企业战略、财务、会计和司库、人力资源、业务发展、投资者关系和信息技术。他于2006年加入Reata。此前，他曾在Caris Diagnostics担任财务副总裁和企业财务总监；以及在Ernst & Young LLP。的健康-科学部门担任高级经理。他持有Henderson 大学的会计学士学位和Central Arkansas大学的工商管理硕士学位。
- Jason D. Wilson is Reata’s Executive Vice President, Operations and oversees program and clinical operations, manufacturing, human resources, bioinformatics, quality and global alliances. Until August 2019 Mr. Wilson was Reata’s Chief Financial Officer. He joined Reata in 2006. Prior to joining Reata, he held positions as Vice President, Finance & Corporate Controller at Caris Diagnostics and as a Senior Manager in the health-sciences group at Ernst & Young LLP. He served on the board of directors of CytoSen Therapeutics, a private company, until its sale to Kiadis Pharmaceuticals. Mr. Wilson holds a B.B.A. in Accounting from Henderson University and an M.B.A. from University of Central Arkansas.
- Michael D. Wortley
Michael D. Wortley，目前是Reata Pharmaceuticals公司（一个临床分期生物制药公司）的首席法务官，也曾从事公司法律35年以上，专注于公司治理事务、收购和资产剥离、公共和私人融资和证券法律事务，包括担任管理职位25年以上。他曾担任Vinson & Elkins公司的德克萨斯达拉斯办公室的合伙人（1995年至2014年），也曾担任多种职务，包括公司的首席运营官，以及达拉斯办公室的管理合伙人。加入Vinson & Elkins公司之前，他曾担任Johnson & Wortley公司的律师（1993年之前称为Johnson & Swanson or Johnson & Gibbs）（1978年至1995年），也曾担任多种职务，包括总裁兼董事会主席。他也曾任职盈利上市公司董事会和非营利理事会。他持有Southern Methodist University的艺术学士和法学博士学位，以及the University of North Carolina at Chapel Hill的区域规划硕士学位。
Michael D. Wortley has served as the Chief Legal Officer for Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since 2015. He has practiced corporate law for over 40 years, focusing primarily on corporate governance matters, acquisitions and divestitures, public and private financings and securities law matters, including over 25 years in management positions. Mr. Wortley was a partner in the Dallas, Texas, office of Vinson & Elkins L.L.P. from 1995 to 2014 and served in various leadership capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office. Prior to joining Vinson & Elkins L.L.P., he was an attorney with Johnson & Wortley, P.C. which prior to 1993 was known as Johnson & Swanson or Johnson & Gibbs from 1978 to 1995 and served in various leadership capacities, including President and Chairman of the Board.- Michael D. Wortley，目前是Reata Pharmaceuticals公司（一个临床分期生物制药公司）的首席法务官，也曾从事公司法律35年以上，专注于公司治理事务、收购和资产剥离、公共和私人融资和证券法律事务，包括担任管理职位25年以上。他曾担任Vinson & Elkins公司的德克萨斯达拉斯办公室的合伙人（1995年至2014年），也曾担任多种职务，包括公司的首席运营官，以及达拉斯办公室的管理合伙人。加入Vinson & Elkins公司之前，他曾担任Johnson & Wortley公司的律师（1993年之前称为Johnson & Swanson or Johnson & Gibbs）（1978年至1995年），也曾担任多种职务，包括总裁兼董事会主席。他也曾任职盈利上市公司董事会和非营利理事会。他持有Southern Methodist University的艺术学士和法学博士学位，以及the University of North Carolina at Chapel Hill的区域规划硕士学位。
- Michael D. Wortley has served as the Chief Legal Officer for Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since 2015. He has practiced corporate law for over 40 years, focusing primarily on corporate governance matters, acquisitions and divestitures, public and private financings and securities law matters, including over 25 years in management positions. Mr. Wortley was a partner in the Dallas, Texas, office of Vinson & Elkins L.L.P. from 1995 to 2014 and served in various leadership capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office. Prior to joining Vinson & Elkins L.L.P., he was an attorney with Johnson & Wortley, P.C. which prior to 1993 was known as Johnson & Swanson or Johnson & Gibbs from 1978 to 1995 and served in various leadership capacities, including President and Chairman of the Board.
- Manmeet S. Soni
Manmeet S. Soni是Reata的首席财务官，负责监督公司战略、财务、会计、财政、税务、企业沟通、投资者关系和信息技术。他于2019年8月加入Reata。加入Reata之前，他曾担任Alnylam Pharmaceuticals, Inc.的高级副总裁兼首席财务官(从2017年5月到2019年8月)。从2016年3月到2017年2月，他担任ARIAD Pharmaceuticals, Inc.(上市生物制药公司)的执行副总裁、首席财务官和财务主管，当时ARIAD被Takeda Pharmaceutical company Limited收购。Soni先生继续担任ARIAD的员工直到2017年5月。此前，Soni先生担任Pharmacyclics, Inc.(一家上市生物制药公司)的首席财务官和财务主管，直到2015年被AbbVie收购。在加入Pharmacyclics之前，他曾担任ZELTIQ Aesthetics Inc.(一家上市的医疗技术公司)的财务总监。加入ZELTIQ之前，Soni先生在PricewaterhouseCoopers的生命科学和风险投资集团工作。他目前担任Pulse Biosciences, Inc.、Arena Pharmaceuticals, Inc.和Summit Therapeutics plc的董事会成员，这些公司都是上市公司。Soni先生毕业于印度德里大学Hansraj学院。他是印度特许会计师协会(Institute of Chartered Accountants of India)的注册会计师和特许会计师。
Manmeet S. Soni is Reata's Chief Financial Officer and oversees corporate strategy, finance, accounting, treasury, tax, corporate communications, investor relations and information technology. He joined Reata in August 2019. Prior to joining Reata, Mr. Soni served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 until August 2019. From March 2016 to February 2017 Mr. Soni served as the Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Mr. Soni continued as an employee of ARIAD through May 2017. Previously, Mr. Soni served as Chief Financial Officer and Treasurer of Pharmacyclics, Inc., a publicly held biopharmaceutical company, until its acquisition by AbbVie in 2015. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly held medical technology company as corporate controller. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers in their Life Science and Venture Capital Group. Mr. Soni currently serves as a member of the board of directors of Pulse Biosciences, Inc., Arena Pharmaceuticals, Inc. and Summit Therapeutics plc, each of which is a publicly traded company. Mr. Soni graduated from Hansraj College at Delhi University in India. He is a CPA certified public accountant and Chartered Accountant from the Institute of Chartered Accountants of India.- Manmeet S. Soni是Reata的首席财务官，负责监督公司战略、财务、会计、财政、税务、企业沟通、投资者关系和信息技术。他于2019年8月加入Reata。加入Reata之前，他曾担任Alnylam Pharmaceuticals, Inc.的高级副总裁兼首席财务官(从2017年5月到2019年8月)。从2016年3月到2017年2月，他担任ARIAD Pharmaceuticals, Inc.(上市生物制药公司)的执行副总裁、首席财务官和财务主管，当时ARIAD被Takeda Pharmaceutical company Limited收购。Soni先生继续担任ARIAD的员工直到2017年5月。此前，Soni先生担任Pharmacyclics, Inc.(一家上市生物制药公司)的首席财务官和财务主管，直到2015年被AbbVie收购。在加入Pharmacyclics之前，他曾担任ZELTIQ Aesthetics Inc.(一家上市的医疗技术公司)的财务总监。加入ZELTIQ之前，Soni先生在PricewaterhouseCoopers的生命科学和风险投资集团工作。他目前担任Pulse Biosciences, Inc.、Arena Pharmaceuticals, Inc.和Summit Therapeutics plc的董事会成员，这些公司都是上市公司。Soni先生毕业于印度德里大学Hansraj学院。他是印度特许会计师协会(Institute of Chartered Accountants of India)的注册会计师和特许会计师。
- Manmeet S. Soni is Reata's Chief Financial Officer and oversees corporate strategy, finance, accounting, treasury, tax, corporate communications, investor relations and information technology. He joined Reata in August 2019. Prior to joining Reata, Mr. Soni served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 until August 2019. From March 2016 to February 2017 Mr. Soni served as the Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Mr. Soni continued as an employee of ARIAD through May 2017. Previously, Mr. Soni served as Chief Financial Officer and Treasurer of Pharmacyclics, Inc., a publicly held biopharmaceutical company, until its acquisition by AbbVie in 2015. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly held medical technology company as corporate controller. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers in their Life Science and Venture Capital Group. Mr. Soni currently serves as a member of the board of directors of Pulse Biosciences, Inc., Arena Pharmaceuticals, Inc. and Summit Therapeutics plc, each of which is a publicly traded company. Mr. Soni graduated from Hansraj College at Delhi University in India. He is a CPA certified public accountant and Chartered Accountant from the Institute of Chartered Accountants of India.
- Dawn C. Bir
Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.- Dawn C. Bir，自2019年3月起担任Geron的董事。自2016年9月起，她担任Reata Pharmaceuticals, Inc.（一家生物制药公司）的首席商务官，在那里她领导营销、市场准入、销售和商业运营。从2013年2月到2016年9月，Bir女士担任Pharmacyclics LLC （AbbVie公司）的销售副总裁，在那里她建立并领导他们的第一个血液学全国销售组织，并负责IMBRUVICA在美国和波多黎各的推出。女士从2011年10月到2013年2月Bir担任销售和营销的副总裁天空制药包装有限公司& Rx Pak，单位在美国制药McKesson分工和专业解决方案公司，全球医疗保健公司，在那里她负责两家公司和收入中心，并领导多个职能，包括销售、市场营销、合同管理、项目管理和客户服务。从1996年到2011年10月，她担任Genentech, Inc.（罗氏集团（全球制药公司）的成员）和Bristol-Myers Squibb company（全球制药公司）的几个商业和销售职位，并不断被提拔。她持有宾厄姆顿大学（Binghamton University）生物学学士学位。
- Dawn C. Bir has served as a director of Geron since March 2019. Since September 2016 Ms. Bir has served as the Chief Commercial Officer of Reata Pharmaceuticals, Inc., a biopharmaceutical company, where she leads marketing, market access, sales, and commercial operations. From February 2013 to September 2016 Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie company, where she built and led their first hematology national sales organization, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. From October 2011 to February 2013 Ms. Bir served as Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within the U.S. pharmaceutical and specialty solutions division of McKesson Corporation, a global healthcare company, where she was responsible for two companies and revenue centers, and led multiple functions, including sales, marketing, contract management, project management and customer service. From 1996 to October 2011 Ms. Bir held several commercial and sales positions of increasing responsibility within Genentech, Inc., a member of the Roche Group, a global pharmaceutical company, and Bristol-Myers Squibb Company, a global pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.